Anaveon

Anaveon is a late-stage preclinical biotechnology company developing engineered antibodies that target central regulatory nodes of the immune system to treat autoimmune diseases. The company's lead program, ANV200, is a precision-engineered antibody designed to selectively eliminate or reprogram PD-1-expressing pathogenic T cells to restore immune balance. These biologics act on upstream immune pathways to address persistent inflammation and restore tissue homeostasis in patients with immune-mediated diseases.